Cargando…

Pro-inflammatory markers predict response to sequential pharmacotherapy in major depressive disorder: a CAN-BIND-1 report

INTRODUCTION: Despite replicated cross-sectional evidence of aberrant levels of peripheral inflammatory markers in individuals with major depressive disorder (MDD), there is limited literature on associations between inflammatory tone and response to sequential pharmacotherapies. OBJECTIVES: To asse...

Descripción completa

Detalles Bibliográficos
Autores principales: Husain, M. I., Foster, J. A., Mason, B. L., Chen, S., Wang, W., Rotzinger, S., Rizvi, S., Ho, K., Lam, R., MacQueen, G., Milev, R., Frey, B. N., Mueller, D., Turecki, G., Jha, M., Trivedi, M., Kennedy, S. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10596235/
http://dx.doi.org/10.1192/j.eurpsy.2023.659
_version_ 1785125056332955648
author Husain, M. I.
Foster, J. A.
Mason, B. L.
Chen, S.
Wang, W.
Rotzinger, S.
Rizvi, S.
Ho, K.
Lam, R.
MacQueen, G.
Milev, R.
Frey, B. N.
Mueller, D.
Turecki, G.
Jha, M.
Trivedi, M.
Kennedy, S. H.
author_facet Husain, M. I.
Foster, J. A.
Mason, B. L.
Chen, S.
Wang, W.
Rotzinger, S.
Rizvi, S.
Ho, K.
Lam, R.
MacQueen, G.
Milev, R.
Frey, B. N.
Mueller, D.
Turecki, G.
Jha, M.
Trivedi, M.
Kennedy, S. H.
author_sort Husain, M. I.
collection PubMed
description INTRODUCTION: Despite replicated cross-sectional evidence of aberrant levels of peripheral inflammatory markers in individuals with major depressive disorder (MDD), there is limited literature on associations between inflammatory tone and response to sequential pharmacotherapies. OBJECTIVES: To assess associations between plasma levels of pro-inflammatory markers and treatment response to escitalopram and adjunctive aripiprazole in adults with MDD. METHODS: In a 16-week open-label clinical trial, 211 participants with MDD were treated with escitalopram 10– 20 mg daily for 8 weeks. Responders continued on escitalopram while non-responders received adjunctive aripiprazole 2–10 mg daily for 8 weeks. Plasma levels of pro-inflammatory markers – C-reactive protein, Interleukin (IL)-1β, IL-6, IL-17, Interferon gamma (IFN)-Γ, Tumour Necrosis Factor (TNF)-α, and Chemokine C–C motif ligand-2 (CCL-2) - measured at baseline, and after 2, 8 and 16 weeks were included in logistic regression analyses to assess associations between inflammatory markers and treatment response. RESULTS: Pre-treatment levels of IFN-Γ and CCL-2 were significantly higher in escitalopram non-responders compared to responders. Pre-treatment IFN-Γ and CCL-2 levels were significantly associated with a lower of odds of response to escitalopram at 8 weeks. Increases in CCL-2 levels from weeks 8 to 16 in escitalopram non-responders were significantly associated with higher odds of non-response to adjunctive aripiprazole at week 16. CONCLUSIONS: Pre-treatment levels of IFN-Γ and CCL-2 were predictive of response to escitalopram. Increasing levels of these pro-inflammatory markers may predict non-response to adjunctive aripiprazole. These findings require validation in independent clinical populations. DISCLOSURE OF INTEREST: None Declared
format Online
Article
Text
id pubmed-10596235
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-105962352023-10-25 Pro-inflammatory markers predict response to sequential pharmacotherapy in major depressive disorder: a CAN-BIND-1 report Husain, M. I. Foster, J. A. Mason, B. L. Chen, S. Wang, W. Rotzinger, S. Rizvi, S. Ho, K. Lam, R. MacQueen, G. Milev, R. Frey, B. N. Mueller, D. Turecki, G. Jha, M. Trivedi, M. Kennedy, S. H. Eur Psychiatry Abstract INTRODUCTION: Despite replicated cross-sectional evidence of aberrant levels of peripheral inflammatory markers in individuals with major depressive disorder (MDD), there is limited literature on associations between inflammatory tone and response to sequential pharmacotherapies. OBJECTIVES: To assess associations between plasma levels of pro-inflammatory markers and treatment response to escitalopram and adjunctive aripiprazole in adults with MDD. METHODS: In a 16-week open-label clinical trial, 211 participants with MDD were treated with escitalopram 10– 20 mg daily for 8 weeks. Responders continued on escitalopram while non-responders received adjunctive aripiprazole 2–10 mg daily for 8 weeks. Plasma levels of pro-inflammatory markers – C-reactive protein, Interleukin (IL)-1β, IL-6, IL-17, Interferon gamma (IFN)-Γ, Tumour Necrosis Factor (TNF)-α, and Chemokine C–C motif ligand-2 (CCL-2) - measured at baseline, and after 2, 8 and 16 weeks were included in logistic regression analyses to assess associations between inflammatory markers and treatment response. RESULTS: Pre-treatment levels of IFN-Γ and CCL-2 were significantly higher in escitalopram non-responders compared to responders. Pre-treatment IFN-Γ and CCL-2 levels were significantly associated with a lower of odds of response to escitalopram at 8 weeks. Increases in CCL-2 levels from weeks 8 to 16 in escitalopram non-responders were significantly associated with higher odds of non-response to adjunctive aripiprazole at week 16. CONCLUSIONS: Pre-treatment levels of IFN-Γ and CCL-2 were predictive of response to escitalopram. Increasing levels of these pro-inflammatory markers may predict non-response to adjunctive aripiprazole. These findings require validation in independent clinical populations. DISCLOSURE OF INTEREST: None Declared Cambridge University Press 2023-07-19 /pmc/articles/PMC10596235/ http://dx.doi.org/10.1192/j.eurpsy.2023.659 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Husain, M. I.
Foster, J. A.
Mason, B. L.
Chen, S.
Wang, W.
Rotzinger, S.
Rizvi, S.
Ho, K.
Lam, R.
MacQueen, G.
Milev, R.
Frey, B. N.
Mueller, D.
Turecki, G.
Jha, M.
Trivedi, M.
Kennedy, S. H.
Pro-inflammatory markers predict response to sequential pharmacotherapy in major depressive disorder: a CAN-BIND-1 report
title Pro-inflammatory markers predict response to sequential pharmacotherapy in major depressive disorder: a CAN-BIND-1 report
title_full Pro-inflammatory markers predict response to sequential pharmacotherapy in major depressive disorder: a CAN-BIND-1 report
title_fullStr Pro-inflammatory markers predict response to sequential pharmacotherapy in major depressive disorder: a CAN-BIND-1 report
title_full_unstemmed Pro-inflammatory markers predict response to sequential pharmacotherapy in major depressive disorder: a CAN-BIND-1 report
title_short Pro-inflammatory markers predict response to sequential pharmacotherapy in major depressive disorder: a CAN-BIND-1 report
title_sort pro-inflammatory markers predict response to sequential pharmacotherapy in major depressive disorder: a can-bind-1 report
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10596235/
http://dx.doi.org/10.1192/j.eurpsy.2023.659
work_keys_str_mv AT husainmi proinflammatorymarkerspredictresponsetosequentialpharmacotherapyinmajordepressivedisorderacanbind1report
AT fosterja proinflammatorymarkerspredictresponsetosequentialpharmacotherapyinmajordepressivedisorderacanbind1report
AT masonbl proinflammatorymarkerspredictresponsetosequentialpharmacotherapyinmajordepressivedisorderacanbind1report
AT chens proinflammatorymarkerspredictresponsetosequentialpharmacotherapyinmajordepressivedisorderacanbind1report
AT wangw proinflammatorymarkerspredictresponsetosequentialpharmacotherapyinmajordepressivedisorderacanbind1report
AT rotzingers proinflammatorymarkerspredictresponsetosequentialpharmacotherapyinmajordepressivedisorderacanbind1report
AT rizvis proinflammatorymarkerspredictresponsetosequentialpharmacotherapyinmajordepressivedisorderacanbind1report
AT hok proinflammatorymarkerspredictresponsetosequentialpharmacotherapyinmajordepressivedisorderacanbind1report
AT lamr proinflammatorymarkerspredictresponsetosequentialpharmacotherapyinmajordepressivedisorderacanbind1report
AT macqueeng proinflammatorymarkerspredictresponsetosequentialpharmacotherapyinmajordepressivedisorderacanbind1report
AT milevr proinflammatorymarkerspredictresponsetosequentialpharmacotherapyinmajordepressivedisorderacanbind1report
AT freybn proinflammatorymarkerspredictresponsetosequentialpharmacotherapyinmajordepressivedisorderacanbind1report
AT muellerd proinflammatorymarkerspredictresponsetosequentialpharmacotherapyinmajordepressivedisorderacanbind1report
AT tureckig proinflammatorymarkerspredictresponsetosequentialpharmacotherapyinmajordepressivedisorderacanbind1report
AT jham proinflammatorymarkerspredictresponsetosequentialpharmacotherapyinmajordepressivedisorderacanbind1report
AT trivedim proinflammatorymarkerspredictresponsetosequentialpharmacotherapyinmajordepressivedisorderacanbind1report
AT kennedysh proinflammatorymarkerspredictresponsetosequentialpharmacotherapyinmajordepressivedisorderacanbind1report